Therapeutic use of MicroRNAs in cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 1, 2016, Pages 7-19

  Tessitore, Alessandra ^a   Cicciarelli, Germana ^a   Mastroiaco, Valentina ^a   Vecchio, Filippo Del ^a   Capece, Daria ^b   Verzella, Daniela ^a   Fischietti, Mariafausta ^a   Vecchiotti, Davide ^a   Zazzeroni, Francesca ^a   Alesse, Edoardo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Cancer; Chemotherapy; MicroRNA; Radiation therapy; Targeted therapy

Indexed keywords

MICRORNA;

ARTICLE; BIOGENESIS; BREAST CANCER; CANCER GROWTH; COLORECTAL CANCER; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; NEOPLASM; NEUROBLASTOMA; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; NEOPLASMS;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84947983650     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150824153358     Document Type: Article

References (160)

1. Marusyk, A.; Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta, 2010, 1805(1), 105-117.
2. Greaves, M.; Maley, C.C. Clonal evolution in cancer. Nature, 2012, 481, 306-313.
3. Huang, H.; Shen, A.; Ding, J.; Geng, M. Molecularly targeted cancer therapy: Some lessons from the past decade. Trends. Pharmacol. Sci., 2014, 35, 41-50.
4. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat. Rev. Drug Discov., 2010, 9(10), 775-789.
5. Di Leva, G.; Garofalo, M.; Croce, C.M. MicroRNAs in cancer. Annu. Rev. Phatol., 2014, 9, 287-314.
6. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanisms, and function. Cell, 2004, 116, 281-297.
7. Ebert, M.S.; Sharp, P.A. Roles for microRNAs in conferring robustness to biological processes. Cell, 2012, 149(3), 515-524.
8. Palanichamy, J.K.; Rao, D.S. MiRNA dysregulation in cancer: Towards a mechanistic understanding. Front. Genet., 2014, 5 (54), 1-10.
9. Valeri, N.; Gasparini, P.; Fabbri, M.; Braconi, C.; Veronese, A.; Lovat, F.; Adair, B.; Vannini, I.; Fanini, F.; Bottoni, A.; Costinean, S.; Sandhu, S.K.; Nuovo, G.J.; Alder, H.; Gafa, R.; Calore, F.; Ferracin, M.; Lanza, G.; Stefano Volinia, S.; Negrini, M.; McIlhatton, M.A.; Amadori, D.; Richard Fishel, R.; Croce, C.M. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA, 2010, 107, 6982-6987.
10. Kong, W.; He, L.; Richards, E.; Challa, S.; Xu, C.; Wey, J.P.; Lancaster, J.; Coppola, D.; Sellers, T.; Djeu, J.Y.; Cheng, J. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triplenegative breast cancer. Oncogene, 2014, 33(6), 679-689.
11. Gasparini, P.; Lovat, F.; Fassan, M.; Casadei, L.; Cascione, L.; Jacob, K.N.; Carasi, S.; Palmieri, D.; Costinean, S.; Shapiro, C.L.; Huebner, K.; Croce, C.M. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc. Natl. Acad. Sci. USA, 2014, 111(12), 4536-4541.
12. Huang, C.; Li, H.; Wu, W.; Jiang, T.; Qiu, Z. Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Oncol. Rep., 2013, 30, 1223-1230.
13. Fu, X.; Han, Y.; Wu, Y.; Zhu, X.; Lu, X.; Mao, F.; Wang, X.; He, X.; Zhao, Y.; Zhao, Y. Prognostic role of microRNA-21 invarious carcinomas: A systematic review and meta-analysis. Eur. J. Clin. Invest., 2011, 41(11), 1245-1253.
14. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133(2), 647-658.
15. Zhang, J.; Wang, J.; Zhao, F.; Liu, Q.; Jiang, K.; Yang, G. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta, 2010, 411, 846-852.
16. Zhang, B.G.; Li, J.F.; Yu, B.Q.; Zhu, Z.G.; Liu, B.Y.; Yan, M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol. Rep., 2012, 27, 1019-1026.
17. Xiong, B.; Cheng, Y.; Ma, L.; Zhang, C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int. J. Oncol., 2013, 42, 219-228.
18. Liu, Z.; Wang, H.; Liu, J.; Wang, Z. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell. Biochem., 2013, 372, 35-45.
19. Bao, L.; Yan, Y.; Xu, C.; Ji, W.; Shen, S.; Xu, G.; Zeng, Y.; Sun, B.; Qian, H.; Chen, L.; Wu, M.; Su, C.; Chen, J. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett., 2013, 337, 226-236.
20. Zhu, S.; Si, M.; Wu, H.; Mo, Y. MicroRNA-21 targets the tumor TPM1 suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem., 2007, 282, 14328-14336.
21. Li, T.; Li, D.; Sha, J.; Sun, P.; Huang, Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun., 2009, 383, 280-285.
22. Li, J.; Huang, H.; Sun, L.; Yang, M.; Pan, C.; Chen, W.; Wu, D.; Lin, Z.; Zeng, C.; Yao, Y.; Zhang, P.; Song, E. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res., 2009, 15(12), 3998-4008.
23. Lu, Z.; Liu, M.; Stribinskis, V.; Klinge, C.M.; Ramos, K.S.; Colburn, N.H.; Li, Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 2008, 27, 4373-4379.
24. Chen, Y.; Liu, W.; Chao, T.; Zhang, Y.; Yan, X.; Gong, Y.; Qiang, B.; Yuan, J.; Sun, M.; Peng, X. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett., 2008, 272, 197-205.
25. Chang, K.N.; Miller, N.; Kheirelseid, E.A.H.; Ingoldsby, H.; Hennessy, E.; Curran, C.E.; Curran, S.; Smith, M.J.; Regan, M.; McAnena, O.J.; Kerin, M.J. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur. J. Surg. Oncol., 2011, 37, 597-603.
26. Cao, Z.; Yoon, J.H.; Nam, S.W.; Lee, J.Y.; Park, W.S. PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J. Cancer Res. Clin. Oncol., 2012, 138, 611-619.
27. Qiu, X.; Dong, S.; Qiao, F.; Lu, S.; Song, Y.; Lao, Y.; Li, Y.; Zeng, T.; Hu, J.; Zhang, L.; Fan, H. HBx-mediated miR-21upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene , 2013, 32(27), 3296-3305.
28. Li, X.; Xin, S.; He, Z.; Che, X.; Wang, J.; Xiao, X.; Chen, J.; Song, X. MicroRNA-21 (miR-21) post transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol. Biochem., 2014, 33, 1631-1642.
29. Concepcion, C.P.; Bonetti, C.; Ventura, A. The miR-17-92 family of microRNA clusters in development and disease. Cancer J., 2012, 18(3), 262-267.
30. Lovén, J.; Zinin, N.; Wahlström, T.; Müller, I.; Brodin, P.; Fredlund, E.; Ribacke, U.; Pivarcsi, A.; Påhlman, S.; Henriksson, M. MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc. Natl. Acad. Sci. USA, 2010, 107(4), 1553-1558.
31. Wu, C.W.; Dong, Y.J.; Liang, Q.Y.; He, X.Q.; Ng, S.S.M.; Chan, F.K.L.; Sung, J.J.Y.; Yu, J. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PlosOne, 2013, 8(2), e57036.
32. Duan, J.H.; Fang, L. MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR. Tumour Biol., 2014, 35(11), 11013-11019.
33. Li, X.; Zhang, Z.; Yu, M.; Li, L.; Du, G.; Xiao, W.; Yang, H. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int. J. Mol. Sci., 2013, 14, 16226-16239.
34. Wu, Q.; Yang, Z.; An, Y.; Hu, H.; Yin, J.; Zhang, P.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis., 2014, 5, e1144.
35. Wu, W; Takanashi, M.; Borjigin, N.; Ohno, S-J.; Fujita, K.; Hoshino, S.; Osaka, Y.; Tsuchida, A.; Kuroda, M. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br. J. Cancer, 2013, 108, 653-661.
36. Wu, Q.; Luo, G.; Yang, Z.; Zhu, F.; An, Y.; Shi, Y.; Fan, D. MiR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett., 2014, 588, 2055-2062.
37. Taguchi, A.; Yanagisawa, K.; Tanaka, M. Identification of Hypoxia-Inducible Factor-1a as a novel target for miR-17-92 microRNA cluster. Cancer Res., 2008; 68, 5540-5545.
38. Garofalo, M.; Quintavalle, C.; Romano, G.; Croce, C.M.; Condorelli, G. miR221/222 in cancer: Their role in tumor progression and response to therapy. Curr. Mol. Med., 2012, 12(1), 27-33.
39. Kip1. J. Biol. Chem., 2007, 282, 23716-23724.
40. Visone, R.; Russo, L.; Pallante, P.; De Martino, I.; Ferraro, A.; Leone, V.; Borbone, E.; Petrocca, F.; Alder, H.; Croce, C.M.; Fusco, A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer, 2007, 14, 791-798.
41. Chun-zhi, Z.; Lei, H.; An-ling, Z.; Yan-chao, F.; Xiao, Y.; Guangxiu, W.; Zhi-fan, J.; Pei-yu, P.; Qing-yu, Z.; Chun-sheng, K. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. Bio. Med. Cent. Cancer, 2010, 10, 367.
42. Zhang, C.; Zhan, J.; Zhang, A.; Shi, Z.; Han, L.; Jia, Z.; Yang, W.; Wang, G.; Jiang, T.; You, Y.; Pu, P.; Cheng, J.; Kang, C. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol. Cancer, 2010, 9, 229.
43. Pineau, P.; Voliniab, S.; McJunkinc, K.; Marchioa, A.; Battistone, C.; Terrisf, B.; Mazzaferroe, V.; Lowe, S.W.; Carlo M. Croce, C.M.; Dejeana, A. MiR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA, 2010, 107(1), 264-269.
44. Quintavalle, C.; Mangani, D.; Roscigno, G.; Romano, G.; Diaz-Lagares, A.; Iaboni, M.; Donnarumma, E.; Fiore, D.; De Marinis, P.; Soini, Y.; Esteller, M.; Condorelli, G. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoSOne, 2013, 8(9), e74466.
45. Gramantieri, L.; Fornari, F.; Ferracin, M.; Veronese, A.; Sabbioni, A.; Calin, G.A.; Grazi, L.; Croce, C.M.; Bolondi, L.; Negrini, M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res., 2009, 15(16), 5073-5081.
46. Biagioni, F.; Ben-Moshe, N.B.; Fontemaggi, G.; Yarden, Y.; Domany, E.; Blandino, G. The locus of microRNA-10b: A critical target for breast cancer insurgence and dissemination. Cell Cycle, 2013, 12, 15, 2371-2375.
47. Xiao, H.; Li, H.; Yu, G.; Xiao, W.; Hu, J.; Tang, K.; Zeng, J.; He, W.; Zeng, G.; Ye, Z.; Xu, H. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. Oncol. Rep., 2014, 31(4), 1832-1838.
48. Ouyang, H.; Gore, J.; Deitz, S.; Korc, M. MicroRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-b actions. Oncogene, 2014, 33, 4664-4674.
49. Zhang, J.; Xu, L.; Yang, Z.; Lu, H.; Hu, D.; Li, W.; Zhang, Z.; Liu, B.; Ma, S.; MicroRNA-10b indicates a poor prognosis of non-small cell lung cancer and targets E-cadherin. Clin. Transl. Oncol., 2015, 17(3), 209-214.
50. Raver-Shapira, N.; Marciano, E.; Meiri, E,; Spector, Y.; Rosenfeld, N.; Moskovits, N.; Bentwich, Z.; Oren, M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell, 2007, 26, 731-743.
51. Chang, T.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J.; Arking, D.E.; Beer, M.A.; Maitra, A.; Mendell, J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell. 2007, 26(5), 745-752.
52. Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ., 2010, 17, 193-199.
53. Wei, J.S.; Song, Y.K.; Durinck, S.; Chen, Q.R.; Cheuk, A.T.C.; Tsang, P.; Zhang, Q.; Thiele, C.J.; Slack, A.; Shohet, J.; Khan, J. The MYCN oncogene is a direct target of miR-34. Oncogene, 2008, 27(39), 5204-5213.
54. Chen, Q.; Yu, L.; Tsang, P.; Wei, J.S.; Song, Y.K.; Cheuk, A.; Chung, J.; Hewitt, S.M.; Veenstra, T.D.; Khan, J. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J. Proteome. Res., 2011, 10(2), 479-487.
55. Li, W.; Ma, M.; Dong, L.; Wang, F.; Chen, L.; Li, X.; MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol. Ther., 2011, 12, 6, 477-483.
56. Mackiewicz, M.; Huppi, K.; Pitt, J.J.; Dorsey, T.H.; Ambs, S.; Caplen, N.J. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res. Treat., 2011, 130(2), 663-679.
57. Lal, A.; Thomas, M.P.; Altschuler, G.; Navarro, F.; O'Day, E.; Li, X.L.; Concepcion, C.; Han, Y.; Thiery, J.; Rajani, D.K.; Deutsch, A.; Hofmann, O.; Ventura, A.; Hide, W.; Lieberman, J. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet., 2011, 7(11), e1002363.
58. Wu, J.; Wu, G.; Lv, L.; Ren, Y.F.; Zhang, X.J.; Xue, Y.F.; Li, G.; Lu, X.; Sun, Z.; Tang, K.F. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis, 2012, 33(3), 519-528.
59. Mandke, P.; Wyatt, N.; Fraser, J.; Bates, B.; Berberich, S.J.; Markey, M.P. Micro-RNA34a modulates MDM4 experession via a target site in the open reading frame. PlosONE, 2012, 7, e42034.
60. Peng, Y.; Guo, J.J.; Liu, Y.M.; Wu, X.L. MicroRNA-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci. Rep., 2014, 34(3), e00112.
61. Boyerinas, B.; Park, S.; Hau, A.; Murmann, A.E.; Peter, M.E. The role of let-7 in cell differentiation and cancer. Endo. Relat. Cancer, 2010, 17, F19-F36.
62. Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom,M.; Jarvis,R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell, 2005, 120, 635-647.
63. Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev., 2007, 21, 1025-1030.
64. Zhao, Y.; Deng, C.; Wang, J.; Xiao, J.; Gatalica, Z.; Recker, R.R.; Xiao, G.G. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res. Treat., 2011, 127, 69-80.
65. Wendler, A.; Keller, d.; Albrecht, C.; Peluso, J.J.; Wehling, M. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol. Rep., 2011, 25, 273-279.
66. Buechner, J.; Tømte, E.; Haug, B.H.; Henriksen, J.R.; Løkke, C.; Flægstad, T.; Einvik, C. Tumour-suppressor micro RNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Brit. J. Cancer, 2011, 105, 296-303.
67. Kent, O.A.; McCall, M.N.; Cornish, T.C.; Halushka, M.K. Lessons from miR-143/145: The importance of cell-type localization of miRNAs. Nucleic Acids Res., 2014, 42(12), 7528-7538.
68. Yan, X.; Chen, X.; Liang, H.; Deng, T.; Chen, W.; Zhang, S.; Liu, M.; Gao, X.; Liu, Y.; Zhao, C.; Wang, X.; Wang, N.; Li, J.; Liu, R.; Zen, K.; Zhang, C.; Liu, B.; Ba, Y. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol. Cancer, 2014, 13, 220.
69. Kojima, S.; Enokida, H.; Yoshino, H.; Itesako, T.; Chiyomaru, T.; Kinoshita, T.; Fuse, M.; Nishikawa, R.; Goto, Y.; Naya, Y.; Nakagawa, M.; Seki, N. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet., 2014, 59(2), 78-87.
70. Wu, X.L.; Cheng, B.; Li, P.Y.; Huang, H.J.; Zhao, Q.; Dan, Z.L.; Tian, D.A.; Zhang, P. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J. Gastroenterol., 2013, 19(43), 7758-7765.
71. Yoshino, H.; Enokida, H.; Itesako, T.; Kojima, S.; Kinoshita, T.; Tatarano, S.; Chiyomaru, T.; Nakagawa, M.; Seki, N. Tumorsuppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci., 2013, 104(12), 1567-1574.
72. Lee, H.K.; Bier, A.; Cazacu, S.; Finniss, S.; Xiang, C.; Twito, H.; Poisson, L.M.; Mikkelsen, T.; Slavin, S.; Jacoby, E.; Yalon, M.; Toren, A.; Rempel, S. A.; Brodie, C. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PlosOne, 2013, 8(2), e54652.
73. Bhattacharya, R.; Nicoloso, M.; Arvizo, R.; Wang, E.; Cortez, A.; Rossi, S.; Calin, G.A.; Mukherjee, P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res., 2009, 69(23), 9090-9095.
74. Cai, C.; Zhao, G.; Tian, L.; Liu, L.; Yan, K.; Ma, Y.; Ji, Z.; Li, X.; Han, K.; Gao, J.; Qiu, X.;, Fan, Q.; Yang, T.; Ma, B. MiR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol. Rep., 2012, 28, 1764-1770.
75. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D'Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De Maria, R. The miR-15amiR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 2008, 14(11), 1271-127.
76. Luo, Q.; Li, X.; Li, J.; Kong, X.; Zhang, J.; Chen, L.; Huang, Y,; Fang, L. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int. J. Oncol., 2013, 43, 1212-1218.
77. Chen, F.; Hou, S.; Fan, H.; Liu, Y. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol. Cell. Biochem., 2014, 391, 11-19.
78. Li, P.; Xie, X.; Chen, Q.; Pang, G.; Luo, W.; Tu, J.; Zheng, F.; Liu, S.; Han, L.; Zhang, J.; Luo, X.; Zhou, X. MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting Synuclein-γ. Asi. Pac. J. Cancer Prev., 2014, 15 (16), 6949-6954.
79. Zhang, S.; Chen, L.; Jung, E.J.; Calin, J.A. Targeting microRNAs with small molecules: Between Dream and Reality. Clin. Pharmacol. Ther., 2010, 87(6), 754-758.
80. Saumet, A.; Mathelier, A.; Lecellier, C.H. The potential of microRNAs in personalized medicine against cancers. Bio.Med. Res. Int., 2014, 642916.
81. Iyer, A.K.; Duan, Z.; Amiji, M.M. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. Mol. Pharmaceutic., 2014, 11, 2511-2526.
82. Yen, S.K.; Padmanabhan, P.; Selvan, S.T. Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery. Theranostics, 2013, 3(12), 986-1003.
83. Shu, Y.; Pi, F.; Sharma, A.; Rajavi, M.; Haqe, F.; Shu, D.; Leggas, M.; Evers, B.M.; Guo, P. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv. Drug. Deliver. Rev., 2014, 66, 74-89.
84. Esquela-Kerscher, A.; Trang, P.; Wiggins, J.F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J.B.; Brown, D.; Bader, A.G.; Slack, F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 2008, 7:6, 759-764.
85. Trang, P.; Medina, P.P.; Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A.G.; Weidhaas, J.B.; Slack, F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010, 29(11), 1580-1587.
86. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther., 2011, 19(6), 1116-1122.
87. Kasinski, A.L.; Slack, F.J. MiRNA-34 prevents cancer initiation and progression in a therapeutically-resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res., 2012, 72(21), 5576-5587.
88. Wu, Y.; Crawford, M.; Mao, Y.; Lee, R.J.; Davis, I.C.; Elton, T.S.; Lee, L.J.; Nana-Sinkam, S.P. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic. Acids, 2013, 2, e84.
89. Hatziapostolou, M.; Polytarchou, C.; Aggelidou, E.; Drakaki, A.; Jaeger, S.A.; Ogata, H.; Karin, M.; Struhl, K.; Hadzopou, M.; Iliopoulos, D. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell, 2011, 147, 1233-1247.
90. Hsu, S.; Yu, B.; Wang, X.; Lu, Y.; Schmidt, C.R.; Lee, R.J.; Lee, L.J.; Jacob, S.T.; Ghoshal, K. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murin liver tumor. Nano Med. J., 2013, 9, 1169-1180.
91. Hou, J.; Lin, L.; Zhou, W.; Wang, Z.; Ding, G.; Dong, Q.; Qin, L.; Wu, X.; Zheng, Y.; Yang, Y.; Tian, W.; Zhang, Q.; Wang, C.; Zhang, Q.; Zhuang, S.; Zheng, L.; Liang, A.; Tao, W.; Cao, X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell, 2011, 19, 232-243.
92. Callegari, E.; Elamin, B.K.; D'Abundo, L.; Falzoni, S.; Donvito, G.; Moshiri, F.; Milazzo, M.; Altavilla, G.; Giacomelli, L.; Fornari, F.; Hemminki, A.; Di Virgilio, F.; Gramantieri, L.; Negrini, M.; Sabbioni, S. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PlosOne, 2013, 8(9), e73964.
93. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; Mendell, J.R.; Mendell, J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137, 1005-1017.
94. Zhang, X.; Liu, S.; Hu, T.; Liu, S.; He, Y.; Sun, S. Up-Regulated microRNA-143 transcribed by Nuclear Factor kappa B enhances hepatocarcinoma metastasis by repressing Fibronectin expression. Hepatology, 2009, 51(2), 490-499.
95. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E.; Feldstein, J.T.; Bell, G.W.; Weinberg, R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol., 2010, 28(4), 341-347.
96. Kim, S.J; Oh, J.S.; Shin, J.Y; Lee, K.D; Sung, K.W.; Nam, S.J.; Chun, K.H. Development of microRNA-145 for therapeutic application in breast cancer. J. Cont. Rel., 2011, 155, 427-434.
97. Li, L.; Xie, X.; Luo, J.; Liu, M.; Xi, S.; Guo, J.; Kong, Y.; Wu, M.; Gao, J.; Xie, Z.; Tang, J.; Wang, X.; Wei, W.; Yang, M.; Hung, M.; Xie, X. Targeted Expression of miR-34a Using the T-VISA System suppresses breast cancer cell growth and invasion. Mol. Ther., 2012, 20(12), 2326-2334.
98. Obad, S.; O dos Santos, C.; Petri, A.; Heidenblad, M.; Broom, O.; Ruse, C.; Fu, C.; Lindow, M.; Stenvang, J.; Straarup, E.M.; Hansen, H.F.; Koch, T.; Pappin, D.; Hannon, G.J.; Kauppinen, S. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet., 2011, 43(4), 371-378.
99. Yang, J.; Zhang, Z.; Chen, C.; Liu, Y.; Si, Q.; Chuang, T.H.; Li, N.; Gomez-Cabrero, A.; Reisfeld, R.A.; Xiang, R.; Luo, Y. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene, 2014, 33(23), 3014-3023.
100. Idogawa, M.; Sasaki, Y.; Suzuki, H. A Single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin. Cancer Res., 2009, 15, 3725-3732.
101. Ibrahim, A.F.; Weirauch, U.; Thomas, M. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res., 2011, 71(15), 5214-5224.
102. Dai, L.; Wang, W.; Zhang, S.; Jiang, Q.; Wang, R.; Dai, L.; Cheng, L.; Yang, Y.; Wei, Y.Q.; Deng, H.X. Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. Cell Biol. Int., 2012, 36(8), 765-770.
103. Zhai, H.; Song, B.; Xu, X.; Zhu, W.; Ju, J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene, 2013, 32(12), 1570-1579.
104. Ye, J.; Wu, X.; Wu, D.; Wu, P.; Ni, C.; Zhang, Z.; Chen, Z.; Qiu, F.; Xu, J.; Huang, J. MiRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PlosOne, 2013, 8(4), e60687.
105. Dong, Y.; Zhao, J.; Wu, C.; Zhang, L.; Liu, X.; Kang, W.; Leung, W.; Zhang, N.; Chan, F.K.L.; Sung, J.J.Y.; Ng, S.S.M.; Yu, J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol. Cancer Res., 2013, 11, 1051-1060.
106. Wang, H.; An, H.; Wang, B.; Liao, Q.; Li, W.; Jin, X.; Cui, S.; Zhang, Y.; Ding, Y.; Zhao, L. miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway. Eur. J. Cancer, 2013, 49, 3924-3935.
107. Bao, Y.; Chen, Z.; Guo, Y.; Feng, Y.; Li, Z.; Han, W.; Wang, J.; Zhao, W.; Jiao, Y.; Li, K.;2, Qian, W.; Wang, J.; Zhang, H.; Wang, L.; Yang, W. Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PlosOne, 2014, 9(8), e105991.
108. Jiang, X.; Du, L.; Wang, L.; Li, J.; Liu, Y.; Zheng, G.; Qu, A.; Zhang, X.; Pan, H.; Yang, Y.; Wang, C. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int. J. Cancer, 2015, 136, 854-862.
109. Henriksen, M.; Johnsen, K.B.; Olesen, P.; Pilgaard, L.; Duroux, M. MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. Neuromol. Med., 2014, 16, 565-577.
110. Thorns, C.; Schurmann, C.; Gebauer, N.; Wallaschofski, H.; Kümpers, C.; Bernard, V.; Feller, A.C.; Keck, T.; Habermann, J.K.; Begum, N.; Lehnert, H.; Brabant, G. Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res., 2014, 34(5), 2249-2254.
111. Gasparini, P.; Cascione, L.; Fassan, M.; Lovat, F.; Guler, G.; Balci, S.; Irkkan, C.; Morrison, C.; Croce, C.M.; Shapiro, C.L.; Huebner, K. MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancer. Oncotarget, 2014, 5(5), 1174-1184.
112. Li, Y.; Xu, J.; Chen, H.; Bai, J.; Li, S.; Zhao, Z.; Shao, T.; Jiang, T.; Ren, H.; Kang, C.; Li, X. Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. Nucleic Acids Res., 2013, 41(22), e203.
113. Chan, M.; Liaw, C.S.; Ji, S.M.; Tan, H.H.; Wong, C.Y.; Thike, A.A.; Tan, P.H.; Ho, G.H.; Lee, A. Identification of circulating microRNA signatures for breast cancer detection. Clin. Cancer Res., 2013, 19, 4477-4487.
114. Gámez-Pozo, A.; Antón-Aparicio, L.M.; Bayona, C.; Borrega, P.; Gallegos Sancho, M.I.; García-Domínguez, R.; De Portugal, T.; Ramos-Vázquez, M.; Pérez-Carrión, R.; Bolós, M.V.; Madero, R.; Sánchez-Navarro, I.; Fresno Vara, J.A.; Espinosa Arranz, E. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia Press, 2012, 14(12), 1144-1152.
115. Bera, A.; VenkataSubbaRao, K.; Manoharan, M.S.; Hill, P.; Freeman, J.W. A miRNA Signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer. PlosOne, 2014, 9(9), e106343.
116. Zhang, J.; Song, W.; Chen, Z.; Wei, J.; Liao, Y.; Lei, J.; Hu, M.; Chen, G.; Liao, B.; Lu, J.; Zhao, H.; Chen, W.; He, Y.; Wang, H.; Xie, D.; Luo, J. Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis. Lancet Oncol., 2013, 14, 1295-1306.
117. Hummel, R.; Hussey, D.J.; Haier, J. MicroRNAs: Predictors and modifiers of chemo-and radiotherapy in different tumor types. Eur. J. Cancer, 2010, 46, 298-311.
118. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D.; AlI, S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat., 2010, 13(3), 57-66.
119. Kim, J.G.; Park, M.T.; Heo, K.; Yang, K.M.; Yi, J.M. Epigenetics meets radiation biology as a new approach in cancer treatment. Int. J. Mol. Sci., 2013, 14, 15059-15073.
120. Pan, B.; Yi, J.; Song, H. MicroRNA-mediated autophagic signaling networks and cancer chemoresistance. Cancer Biother. Radio., 2013, 28(8), 573-578.
121. Migliore, C.; Giordano, S. Resistance to targeted therapies: A role for microRNAs? Trends Mol. Med., 2013, 19(10), 633-642.
122. Ceppi, P.; Mudduluru, G.; Kumarswamy, R.; Rapa, I.; Scagliotti, G.V.; Papotti, M.; Allgayer, H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res., 2010, 8, 1207-1216.
123. Bian, H.; Pan, X.; Yang, J.; Wang, Z.; De, W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res., 2011, 30, 20.
124. Xu, L.; Huang, Y.; Chen, D.; He, J.; Zhu, W.; Zhang, Y.; Liu, X. Downregulation of miR-21 increases cisplatin sensitivity of nonesmall-cell lung cancer. Cancer Genet., 2014, 207, 214-220.
125. Ma, Y.; Xia, H.; Liu, Y.; Li, M. Silencing miR-21 sensitizes nonsmall cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. Bio. Med. Res. Int., 2014, 617-868.
126. Shen, H.; Zhu, F.; Liu, J.; Xu, T.; Pei, D.; Wang, R.; Qian, Y.; Li, Q.; Wang, L.; Shi, Z.; Zheng, J.; Chen, Q.; Jiang, B.; Shu, Y. Alteration in mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PlosOne, 2014, 9(7), e103305.
127. Huang, J.Y.; Cui, S.Y.; Chen, Y.T.; Song, H.Z.; Huang, G.C.; Feng, B.; Sun, M.; De, W.; Wang, R.; Chen, L.B. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One , 2013, 8(8), e72615.
128. Li, J.; Wang, Y.; Song, Y.; Fu, Z.; Yu, W. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol. Cancer, 2014, 13,193.
129. Zhang, Z.; Zhang, L.; Yin, Z.; Fan, X.; Hu, B.; Wang, L.; Zhang, D. MiR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int. J. Clin. Exp. Pathol., 2014, 7(10), 7236-7241.
130. Chen. S.; Wang, H.; Ng, W.L.; Curran, W.J.; Wang, Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81(5), 1524-1529.
131. Duan, W.; Xu, Y.; Dong Y.; Cao, L.; Tong, J.; Zhou, X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J. Radiat. Res., 2013, 54, 611-619.
132. Liu, Y.; Lin, Y.; Chen, Y.; Luo, E.; Sher, Y.; Tsai, M.; Chuang, E.Y.; Lai, L. MicroRNA-449a enhances radiosensitivity in CL1-0 lung adenocarcinoma cells. Plos One, 2013, 8(4), e62383.
133. Kang, J.; Kim, E.; Kim, W.; Seong, K.M.; Youn, H.; Kim, J.W.; Kim, J.; Youn, B. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J. Biol. Chem., 2013, 288(38), 27343-27357.
134. Ma, K.; He, Y.; Zhang, H.; Fei, Q.; Niu, D.; Wang, D.; Ding, X.; Xu, H.; Chen, X.; Zhu, J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J. Biol. Chem., 2012, 287(8), 5639-5649.
135. Xu, N.; Zhang, J.; Shen, C.; Luo, Y.; Xia, L.; Xue, F.; Xia, Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun., 2012, 423, 826-831
136. Xu, Y.; An, Y.; Wang, Y.; Zhang, C.; Zhang, H.; Huang, C.; Jiang, H.; Wang, X.; Li, X. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep., 2013, 29, 2019-2024.
137. Xu, N., Shen, C.; Luo, Y.; Xia, L.; Xue, F.; Xia, Q.; Zhang, J. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem. Biophys. Res. Commun., 2012, 425, 468-472.
138. Yang, F.; Li, Q.; Gong, Z.; Zhou, L.; You, N.; Wang, S.; Li, X.; Li, J.; An, J.; Wang, D.; He, Y.; Dou, K. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol. Cancer Res. Treat., 2014, 13, 77-86.
139. Qin, J.; Luo, M.; Qian, H.; Chen, W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene, 2014, 538, 342-347.
140. Zhao, N.; Wang, R.; Zhou, L.; Zhu, Y.; Gong, J.; Zhuang, S. MicroRNA-26b suppresses the NFκB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol. Cancer, 2014, 13, 1-35.
141. Tsang, T.Y.; Tang, W.Y.; Chan, J.Y.W.; Co, N.N.; Yeung, C.L.A.; Yau, P.L.; Kong, S.K.; Fung, K.P.; Kwok, T.T. P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of mir-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis, 2011, 16, 524-535.
142. Yang, W.; Sun, T.; Cao, J.; Liu, F.; Tian, Y.; Zhu, W. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp. Cell Res., 2012, 318, 944-954.
143. Yang, W.; Wei, J.; Sun, T.; Liu, F. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat. Oncol., 2013, 8, 102.
144. Liang, Z.; Li, Y.; Huang, K.; Wagar, N.; Shim, H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm. Res., 2011, 28(12), 3091-3100.
145. Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem., 2011, 286, 19127-19137.
146. Deng, X.; Cao, M.; Zhang, J.; Hu, K.; Yin, Z.; Zhou, Z.; Xiao, X.; Yang, Y.; Sheng, W.; Wua, Y.; Zeng, Y. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials, 2014, 35, 4333-4344.
147. Liang, Z.; Ahn, J.; Guo, D.; Votaw, J.R.; Shim, H. MicroRNA-302 Replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm. Res., 2013, 30(4), 1008-1016.
148. Yang, G.; Wu, D.; Zhu, J.; Jiang, O.; Shi, Q.; Tian, J.; Weng, Y. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol. Rep., 2013, 30, 877-889.
149. Huang, X.; Taeb, S.; Jahangiri, S.; Emmenegger, U.; Tran, E.; Bruce, J.; Mesci, A.; Korpela,E.; Vesprini, D.; Wong, C.S.; Bristow, R.G.; Liu, F.; Liu, S.K. MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res., 2013, 73, 6972-6986.
150. Song, B.; Wang, Y.; Xi, Y.; Kudo, K.; Bruheim, S.; Botchkina, G.L.: Gavin, E.; Wan, Y.; Formentini, A.; Kornmann, M.; Fodstad, O.; Ju, J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene, 2009, 28(46), 4065-4074.
151. Li, J.; Chen, Y.; Zhao, J.; Kong, F.; Zhang, Y. MiR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett., 2011, 304, 52-59.
152. Zhou, Y.; Wan, G.; Spizzo, R.; Ivan, C.; Mathur, R.; Hu, X.; Ye, X.; Lu, J.; Fan, F.; Xia, L.; Calin, G.A.; Ellis, L.M.; Lu, X. MiR-203 induces oxaliplatin resistance in colorectalc ancer cells by negatively regulating ATM kinase. Mol. Oncol., 2014, 8, 83-92.
153. Li, J.; Zhang, Y.; Zhao, J.; Kong, F.; Chen, Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol. Cell Biochem., 2011, 357, 31-38.
154. Nishida, N.; Yamashita, S.; Mimori, K.; Sudo, T.; Fumiaki Tanaka, F.; Shibata, K.; Yamamoto, H.; Ishii, H.; Doki, Y.; Mori, M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann. Surg. Oncol., 2012, 19, 3065-3071.
155. Qian, X.; Yu, J.; Yin, Y.; He, J.; Wang, L.; Li, Q.; Zhang, L.; Li, C.; Shi, Z.; Xu, Q.; Li, W.; Lai, L.; Liu, L.; Jiang, B. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle, 2013, 12, 9, 1385-1394.
156. Karaayvaz, M.; Zhai, H.; Ju, J. MiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis., 2013, 4, e659.
157. Shang, J.; Yang, F.; Wang, Y.; Wang, Y.; Xue, G.; Mei, Q.; Wang, F.; Sun, S. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/Caspase-9 apoptotic pathway in colorectal cancer cells. J. Cell. Biochem., 2014, 115, 772-784.
158. Xue, Q.; Sun, K.; Deng, H-J.; Lei, S-T.; Dong, J-Q.; Li, G-X. AntimiRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. World J. Gastroenterol., 2013, 19(48), 9307-9317.
159. Zhang, Y.; Zheng, L.; Huang, J.; Gao, F.; Lin, X.; He, L.; Li, D.; Li, Z.; Ding, Y.; Chen, L. MiR-124 radiosensitizes human colorectal cancer cells by targeting PRRX1. Plos One, 2014, 9(4), e93917.
160. Janssen, H.L.A.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K; Van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; Persson, R.; King, B.D.; Kauppinen, S.; Levin, A.A.; Hodges, M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med., 2013, 368, 18, 1685-1694.